Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Biosimilars Month in Review: March 2024
April 3rd 2024In March, FDA approved biosimilar versions of established biologic drugs for autoimmune diseases and skeletal-related events, adalimumab biosimilars demonstrated sustained efficacy and acceptance among patients, and affirmed CT-P41’s potential as an alternative treatment options in clinical practice.
Read More
Rheumatology Month in Review: March 2024
April 2nd 2024This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.
Read More
Guselkumab Improves Pain, Physical Function in Patients with Treatment-Resistant PsA
March 9th 2024A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.
Read More
Approximately Half of Patients Continued Treatment with Adalimumab Biosimilar ABP 501 at 1 Year
March 6th 2024Patients who were naïve to adalimumab tended to switch to other targeted therapies, while those who had been previously treated with adalimumab were more likely to switch back to the reference product.
Read More